CALX · Calix, Inc · Insider Trading

The automatically awarded option vests and becomes exercisable with respect to 25% of the shares of common stock underlying the option on each anniversary of the date of grant (September 28, 2026).

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.795 to $36.74, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

The automatically awarded option vests and becomes exercisable with respect to 25% of the shares of common stock underlying the option on each anniversary of the date of grant (June 29, 2026).

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

Represents a grant of restricted stock units ("RSUs") awarded pursuant to the issuer's non-employee director equity compensation policy, that will vest in full one day prior to the issuer's next annual stockholder meeting. Each RSU represents a contingent right to receive one share of the issuer's common stock.

Amount of securities beneficially owned includes 4,967 unvested RSUs.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.72 to $43.76, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.615 to $43.59, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

The automatically awarded option vests and becomes exercisable with respect to 25% of the shares of common stock underlying the option on each anniversary of the date of grant (March 30, 2026).

100% of the shares subject to the option were fully vested and exercisable on May 22, 2024.

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Calix, Inc. Amended and Restated Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 15, 2025 through February 14, 2026. This transaction is exempt under Rule 16b-3(c).

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2026, the last trading day of the purchase period.

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Calix, Inc. Amended and Restated Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 15, 2025 through February 14, 2026. This transaction is exempt under Rule 16b-3(c).

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2026, the last trading day of the purchase period.

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Calix, Inc. Amended and Restated Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 15, 2025 through February 14, 2026. This transaction is exempt under Rule 16b-3(c).

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2026, the last trading day of the purchase period.

On January 31, 2025, the reporting person was granted a performance-based option to purchase 217,500 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

On January 31, 2025, the reporting person was granted a performance-based option to purchase 170,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.34 to $47.33, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.38 to $48.20, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

100% of the shares subject to the option were fully vested and exercisable on October 1, 2021.

100% of the shares subject to the option were fully vested and exercisable on May 22, 2024.

The automatically awarded option vests and becomes exercisable with respect to 25% of the shares of common stock underlying the option on each anniversary of the date of grant (January 2, 2026).

100% of the shares subject to the option were fully vested and exercisable on May 22, 2024.

100% of the shares subject to the option were fully vested and exercisable on May 22, 2024.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.295, inclusive. Full information on the number of shares sold at each sale price is available upon request.

100% of the shares subject to the option were fully vested and exercisable on February 14, 2023.

100% of the shares subject to the option were fully vested and exercisable on October 1, 2021.

100% of the shares subject to the option were fully vested and exercisable on May 22, 2024.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

100% of the shares subject to the option were fully vested and exercisable on August 1, 2022.

Sales reported on the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 25, 2025.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $65.025 to $65.685, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Sales reported on the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 25, 2025.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $65.45 to $66.325, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.

Sales reported on the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 25, 2025.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $64.44 to $65.40, inclusive. Full information on the number of shares sold at each sale price is available upon request.

Shares held by The Crescentico Trust, Carl Russo, Trustee.